ProtoKinetix Begins Cardiovascular Research

MARIETTA, Ohio–(BUSINESS WIRE)–#privateplacement–ProtoKinetix, Incorporated (
(the “Company” or “ProtoKinetix”) (OTCQB:PKTX)
Is pleased to announce the launch of a proof of concept study in the
field of cardiovascular sciences.

Dr. Thomas Pulinilkunnil, Associate Professor, Department of
Biochemistry and Molecular Biology, Dalhousie University is the
principal investigator on this project. Pulinilkunnil laboratory will
screen and examine the therapeutic utility of PKX-001 (AAGP®) against
inflammatory, hypertrophic and ischemic pathologies in the heart . Upon
the completion of this phase of testing, pre-clinicalscreening of organ
preservation and metabolic effects of PKX-001 will be undertaken in
transplant ready cardiac tissue. The overarching goal of this project is
to develop PKX-001 as a cardioprotective agent with wide ranging
applications in cardiovascular medicine.

About ProtoKinetix, Incorporated

ProtoKinetix is a molecular biotechnology company that has developed and
patented a family of hyper stable, potent glycopeptides (AAGP®) that
enhance both engraftment and protection of transplanted cells used in
regenerative medicine. Due to the results achieved over the last four
years of testing, the University of Alberta has begun Phase 1 human
clinical trials. Additional studies will be expanded to include whole
organ transplantation and all therapies that are being developed
globally to date; cancer, diabetes, retinal degeneration, and cardiac
muscle repair.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward
looking statements” within the meaning of Section 27A of the Securities
Act of 1933 (the “Securities Act”) and Section 21E of the Securities
Exchange Act of 1934 (the “Exchange Act”).
All statements, other
than statements of historical facts, included herein concerning, among
other things, planned capital expenditures, future cash flows and
borrowings, pursuit of potential acquisition opportunities, our
financial position, business strategy and other plans and objectives for
future operations, are forward looking statements. These forward looking
statements are identified by their use of terms and phrases such as
“may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,”
“achievable,” “anticipate,” “will,” “continue,” “potential,” “should,”
“could,” and similar terms and phrases.
Although we believe that
the expectations reflected in these forward looking statements are
reasonable, they do involve certain assumptions, risks and uncertainties
and are not (and should not be considered to be) guarantees of future
Among these risks are those set forth in a Form 10-K
filed on March 9, 2018. It is important that each person reviewing this
release understand the significant risks attendant to the operations of
ProtoKinetix. ProtoKinetix disclaims any obligation to update any
forward-looking statement made here.


ProtoKinetix, Incorporated
Clarence E. Smith, 304-299-5070
and Chief Executive Officer